Renal sympathetic denervation: a new treatment strategy in the management of refractory arterial hypertension
Denervación simpática de arterias renales: una nueva estrategia terapéutica en el manejo de la hipertensión arterial refractaria
Read
7861
Timeswas read the article
2388
Total PDF
5473
Total HTML
Share statistics
array:20 [ "pii" => "X2013251412002017" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2012.Jul.11572" "estado" => "S300" "fechaPublicacion" => "2012-09-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2012;32:555-7" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4486 "formatos" => array:3 [ "EPUB" => 331 "HTML" => 3398 "PDF" => 757 ] ] "Traduccion" => array:1 [ "es" => array:17 [ "pii" => "X021169951200201X" "issn" => "02116995" "doi" => "10.3265/Nefrologia.pre2012.Jul.11572" "estado" => "S300" "fechaPublicacion" => "2012-09-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2012;32:555-7" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 12507 "formatos" => array:3 [ "EPUB" => 312 "HTML" => 11557 "PDF" => 638 ] ] "es" => array:9 [ "idiomaDefecto" => true "titulo" => "Denervación simpática de arterias renales: una nueva estrategia terapéutica en el manejo de la hipertensión arterial refractaria" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "555" "paginaFinal" => "557" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Renal sympathetic denervation: a new treatment strategy in the management of refractory arterial hypertension" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Pedro Aranda-Lara, M. Dolores Martínez-Esteban, José J. Muñoz, Domingo Hernández-Marrero" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Pedro" "apellidos" => "Aranda-Lara" ] 1 => array:2 [ "nombre" => "M. Dolores" "apellidos" => "Martínez-Esteban" ] 2 => array:2 [ "nombre" => "José J." "apellidos" => "Muñoz" ] 3 => array:2 [ "nombre" => "Domingo" "apellidos" => "Hernández-Marrero" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "X2013251412002017" "doi" => "10.3265/Nefrologia.pre2012.Jul.11572" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412002017?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X021169951200201X?idApp=UINPBA000064" "url" => "/02116995/0000003200000005/v0_201502091343/X021169951200201X/v0_201502091343/es/main.assets" ] ] "itemSiguiente" => array:17 [ "pii" => "X2013251412002009" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2012.Jun.11396" "estado" => "S300" "fechaPublicacion" => "2012-09-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2012;32:558-72" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 13264 "formatos" => array:3 [ "EPUB" => 284 "HTML" => 11802 "PDF" => 1178 ] ] "en" => array:12 [ "idiomaDefecto" => true "titulo" => "Biological markers of nephrotic syndrome: a few steps forward in the long way" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "558" "paginaFinal" => "572" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Biomarcadores en el síndrome nefrótico: algunos pasos más en el largo camino" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig1" "etiqueta" => "Tab. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "copyright" => "Elsevier España" "figura" => array:1 [ 0 => array:4 [ "imagen" => "11396_16025_35186_en_t111396_copy1.jpg" "Alto" => 1119 "Ancho" => 2176 "Tamanyo" => 707073 ] ] "descripcion" => array:1 [ "en" => "List of characteristics and potential usefulness of the primary biological markers proposed for the study of nephrotic syndrome" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Alfonso Segarra-Medrano, Clara Carnicer-Cáceres, M. Antonia Arbós-Via, M. Teresa Quiles-Pérez, Irene Agraz-Pamplona, Elena Ostos-Roldán" "autores" => array:6 [ 0 => array:2 [ "nombre" => "Alfonso" "apellidos" => "Segarra-Medrano" ] 1 => array:2 [ "nombre" => "Clara" "apellidos" => "Carnicer-Cáceres" ] 2 => array:2 [ "nombre" => "M. Antonia" "apellidos" => "Arbós-Via" ] 3 => array:2 [ "nombre" => "M. Teresa" "apellidos" => "Quiles-Pérez" ] 4 => array:2 [ "nombre" => "Irene" "apellidos" => "Agraz-Pamplona" ] 5 => array:2 [ "nombre" => "Elena" "apellidos" => "Ostos-Roldán" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "X0211699512002001" "doi" => "10.3265/Nefrologia.pre2012.Jun.11396" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699512002001?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412002009?idApp=UINPBA000064" "url" => "/20132514/0000003200000005/v0_201502091606/X2013251412002009/v0_201502091606/en/main.assets" ] "en" => array:9 [ "idiomaDefecto" => true "titulo" => "Renal sympathetic denervation: a new treatment strategy in the management of refractory arterial hypertension" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "555" "paginaFinal" => "557" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "Pedro Aranda-Lara, M. Dolores Martínez-Esteban, José J. Muñoz, Domingo Hernández-Marrero" "autores" => array:4 [ 0 => array:4 [ "nombre" => "Pedro" "apellidos" => "Aranda-Lara" "email" => array:1 [ 0 => "pedro.aranda.sspa@juntadeandalucia.es" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 1 => array:3 [ "nombre" => "M. Dolores" "apellidos" => "Martínez-Esteban" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] 2 => array:3 [ "nombre" => "José J." "apellidos" => "Muñoz" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] 3 => array:3 [ "nombre" => "Domingo" "apellidos" => "Hernández-Marrero" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] ] "afiliaciones" => array:2 [ 0 => array:3 [ "entidad" => "Unidad de HTA y Riesgo Vascular. Servicio de Nefrología, Hospital Regional Universitario Carlos Haya, Málaga, " "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] 1 => array:3 [ "entidad" => "Servicio de Radiología Vascular Intervencionista, Hospital Regional Universitario Carlos Haya, Málaga, " "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "affb" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Denervación simpática de arterias renales: una nueva estrategia terapéutica en el manejo de la hipertensión arterial refractaria" ] ] "textoCompleto" => "<p class="elsevierStylePara">Although the therapeutic management of arterial hypertension (AHT), which is a public health issue due to its importance in terms of patient health and socioeconomic impacts, has improved somewhat in Spain,<span class="elsevierStyleSup">1,2</span> there are still substantial gaps in our ability to control this entity.</p><p class="elsevierStylePara">Non-compliance, therapeutic inertia, insufficient or inadequate anti-hypertensive treatment, and the characteristics inherent to each form of AHT are recognised as factors that contribute to the inadequate control of AHT, and the consequent increase in vascular morbidity and mortality rates.</p><p class="elsevierStylePara">One of the forms of AHT that implies the highest rates of morbidity and mortality, in addition to increased direct and indirect costs derived from diagnosis and treatment, is refractory or resistant AHT (defined as AHT in which, despite a treatment based on the application of a series of diet restrictions and lifestyle changes along with the adequate use of at least 3 anti-hypertensive drugs –one of which must be a diuretic-, blood pressure remains uncontrolled).<span class="elsevierStyleSup">3,4</span> Although no studies have been specifically designed to measure the prevalence of AHT in hypertensive patients, the estimated prevalence is 10%-15%,<span class="elsevierStyleSup">3,5</span> with rates 2 times higher in certain sub-groups of hypertensive subjects, such as obese patients, diabetics, chronic renal failure patients, and sleep apnoea syndrome patients.<span class="elsevierStyleSup">3,4</span> Adequate treatment of these patients reduces significantly the percentage of cases of hypertension that are truly refractory to treatment. Even so, in spite of protocols involving detailed anamnesis and diagnostic measures, the application of a gamut of hygienic/dietetic methods for making heart-healthy changes in patient lifestyles, and the prescription of multiple combinations (5 or more) of anti-hypertensive drugs with complementary mechanisms of action at appropriate doses, approximately 2%-4% of hypertensive patients do not have their blood pressure (BP) under control, with values surpassing 140mm Hg, and a very high risk of target organ damage and/or developing vascular complications.<span class="elsevierStyleSup">3,4</span></p><p class="elsevierStylePara">In recent years, the search for cost-effective solutions for managing these patients has expanded into non-pharmacological treatment alternatives: one of these is based on radio-frequency ablation of the afferent and efferent sympathetic nerves of the renal arteries (renal sympathetic denervation [RSDN]),<span class="elsevierStyleSup">6</span> and another one is based on parasympathetic activation of the carotid baroreceptors through electrical stimulation (Rheos<span class="elsevierStyleSup">®</span> system).<span class="elsevierStyleSup">7</span> In conjunction with anti-hypertensive medication, both techniques appear to produce positive results, reaching a significantly better control of BP in these cases of severe refractory hypertension; however, the ease of technical application makes RSDN the most commonly used technique with the greatest basis in clinical evidence.<span class="elsevierStyleSup">8</span></p><p class="elsevierStylePara">What are the rational bases for using RSDN as a treatment alternative in severe refractory hypertension patients? The fundamental basis of this treatment strategy is the central role that sympathetic hyperactivity plays in the development and maintenance of AHT, as well as in contributing to structural vascular and organ damage, along with altered carbohydrate and lipid metabolism.<span class="elsevierStyleSup">9</span> In addition, the afferent and efferent renal sympathetic nerves contribute to the increase in sympathetic activity. Through the sympathetic nervous system, the kidneys actively participate in modulating sympathetic activity, both in the development of AHT and its cardiovascular complications.<span class="elsevierStyleSup">10,11</span> Finally, the cost-effectiveness and the usefulness of RSDN as a coadjuvant therapy along with anti-hypertensive medication for refractory AHT is evidenced by the clinical benefits (better control of BP) derived from the application of this treatment to more than 5000 patients to date.<span class="elsevierStyleSup">12</span></p><p class="elsevierStylePara">Data from the clinical trials Simplicity HTN-1<span class="elsevierStyleSup">13,14</span> and Simplicity HTN-2<span class="elsevierStyleSup">15</span> show the short-term and long-term (up to 36 months)<span class="elsevierStyleSup">16</span> anti-hypertensive effects and safety of this therapeutic approach.</p><p class="elsevierStylePara">The results from the Simplicity HTN-1, the first non-randomised clinical trial that initially included only 45 patients with refractory hypertension, showed a mean decrease in systolic and diastolic BP of -25mm Hg and -12mm Hg, respectively, after 6 months on the treatment protocol. When the sample size of this study was amplified to 153 patients,<span class="elsevierStyleSup">14</span> the mean decreases in systolic and diastolic BP were -32mm Hg and -14mm Hg, respectively, after 2 years of follow-up, and BP control (<140/90mm HG) at 39% after 12 months, which remained unchanged 2 years later and was even accompanied by an increase in the initial number of non-responsive patients.<span class="elsevierStyleSup">14</span> These results are accompanied by an excellent safety profile, with only 3% of treated patients developing some kind of secondary side effect in the form of one case of renal artery dissection and another case of progression of a prior renal artery stenosis.<span class="elsevierStyleSup">13</span></p><p class="elsevierStylePara">Equally significant results were obtained by the Simplicity HTN-2,<span class="elsevierStyleSup">14</span> which was a 1:1 randomised study (test group: control group) including 106 hypertensive patients that were refractory to treatment with 5 or more anti-hypertensive drugs at high doses. As compared to the control group, which did not significantly vary in its BP values, the patients that underwent RSDN had progressive decreases in BP until reaching a mean decrease of systolic and diastolic BP of -32mm Hg and -12mm HG, respectively, after 12 months. After only 6 months, 39% of test patients already had a systolic BP<140mm Hg, and 20% required a decrease in anti-hypertensive medication dosage.<span class="elsevierStyleSup">15</span> However, 10% of patients received no benefit from RSDB, with the mean decrease in systolic BP lower than 10mm Hg.<span class="elsevierStyleSup">15</span> Along this same topic, the current issue of <span class="elsevierStyleItalic">Nefrología </span>presents a clinical case of refractory AHT that was resistant to multiple anti-hypertensive drugs and that, after undergoing RSDN, an additional reduction in systolic and diastolic BP of -22mm Hg was achieved, which without a doubt contributes to the mid-term and long-term decrease in the vascular risk of the patient.</p><p class="elsevierStylePara">As regards the technique, the application of the endovascular procedure is not complex: a femoral approach is used to access both renal arteries, and radiofrequency ablation is applied to the sympathetic innervation of these arteries every 5mm circumferentially from the distal zone to the ostial zone. Even though the technique is quite simple, it is not without its limitations and contraindications,<span class="elsevierStyleSup">8</span> requiring a prior evaluation of the anatomy of the main renal arteries; the procedure is contraindicated in the case of multiple renal arteries, a principal renal artery with a diameter <4mm or a length <20mm, and in cases of a previous stent or stenosis. In addition, this procedure is contraindicated in patients with type 1 diabetes, an estimated glomerular filtration rate <45ml/min/1.73m<span class="elsevierStyleSup">2</span>, unstable angina, acute myocardial infarction, or stroke within the last 3-6 months.<span class="elsevierStyleSup">8</span></p><p class="elsevierStylePara">In addition to its anti-hypertensive effects, preliminary studies show that RSDN appears to provide cardiovascular and metabolic benefits that go beyond its anti-hypertensive effects in sub-groups of hypertensive patients with sympathetic hyperactivity, such as those with altered carbohydrate metabolism, sleep apnoea syndrome, heart failure, chronic renal failure, and hepatorenal syndrome.<span class="elsevierStyleSup">8,16-18</span> This is certainly a field open to investigation, necessitating larger randomised studies to ascertain the possible mid-term and long-term benefits of this procedure.</p><p class="elsevierStylePara">Apart from its limitations and contraindications, a series of criteria for patient eligibility exists, although these criteria are not completely well-defined, for administering RSDN to patients with refractory hypertension.</p><p class="elsevierStylePara">Without a doubt, the first criteria is to rule out the existence of pseudo-resistance, which requires a complete evaluation of the patient, including confirming the resistance to standard treatment with an ambulatory BP measurement for 24 hours, correcting exogenous factors that could maintain an elevated BP, and certifying that the possibilities for controlling BP using combinations of multiple complementary anti-hypertensive drugs at high doses have been exhausted,<span class="elsevierStyleSup">8</span> rather than being satisfied with a systolic BP ≥160mm Hg (or ≥150mm Hg for diabetics) and the use of 3 or more anti-hypertensive drugs, as was initially proposed by certain authors.<span class="elsevierStyleSup">4,8</span> We also believe that in candidates for RSDN, we must monitor damage indicators in affected organs that corroborate with the severity of AHT,<span class="elsevierStyleSup">19</span> and that the cost-efficacy and cost-effectiveness of the procedure must be evaluated on an individual patient basis.</p><p class="elsevierStylePara">It goes without saying that the procedure must be carried out in hospitals by personnel with sufficient experience in the management of these patients and these endovascular techniques.<span class="elsevierStyleSup">8</span></p><p class="elsevierStylePara">Finally, although the RSDN technique appears to be quite promising, there are still unanswered questions referring to certain aspects such as the identification of direct predictors for treatment success, testing the effectiveness of RSDN mid-procedure, methods for evaluating a possible process of re-innervation, evaluation of effects on target organs, and the efficacy of other procedures that might produce denervation (ultrasound, micro-wave, laser, cryotherapy, etc.).</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara"><span class="elsevierStyleBold">Conflicts of interest</span></p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">The authors have no conflicts of interest to declare.</p>" "pdfFichero" => "P1-E543-S3680-A11572-EN.pdf" "tienePdf" => true ] "idiomaDefecto" => "en" "url" => "/20132514/0000003200000005/v0_201502091606/X2013251412002017/v0_201502091606/en/main.assets" "Apartado" => array:4 [ "identificador" => "35428" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Editorial Comments" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/20132514/0000003200000005/v0_201502091606/X2013251412002017/v0_201502091606/en/P1-E543-S3680-A11572-EN.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412002017?idApp=UINPBA000064" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 7 | 8 | 15 |
| 2024 October | 36 | 28 | 64 |
| 2024 September | 49 | 25 | 74 |
| 2024 August | 64 | 53 | 117 |
| 2024 July | 35 | 31 | 66 |
| 2024 June | 69 | 38 | 107 |
| 2024 May | 52 | 33 | 85 |
| 2024 April | 45 | 30 | 75 |
| 2024 March | 42 | 29 | 71 |
| 2024 February | 33 | 32 | 65 |
| 2024 January | 38 | 20 | 58 |
| 2023 December | 22 | 25 | 47 |
| 2023 November | 29 | 27 | 56 |
| 2023 October | 31 | 23 | 54 |
| 2023 September | 25 | 37 | 62 |
| 2023 August | 30 | 14 | 44 |
| 2023 July | 29 | 26 | 55 |
| 2023 June | 40 | 17 | 57 |
| 2023 May | 39 | 31 | 70 |
| 2023 April | 21 | 11 | 32 |
| 2023 March | 29 | 22 | 51 |
| 2023 February | 30 | 25 | 55 |
| 2023 January | 29 | 24 | 53 |
| 2022 December | 47 | 20 | 67 |
| 2022 November | 42 | 31 | 73 |
| 2022 October | 35 | 43 | 78 |
| 2022 September | 48 | 24 | 72 |
| 2022 August | 51 | 47 | 98 |
| 2022 July | 42 | 39 | 81 |
| 2022 June | 43 | 34 | 77 |
| 2022 May | 37 | 39 | 76 |
| 2022 April | 43 | 47 | 90 |
| 2022 March | 47 | 42 | 89 |
| 2022 February | 31 | 40 | 71 |
| 2022 January | 26 | 21 | 47 |
| 2021 December | 35 | 43 | 78 |
| 2021 November | 31 | 34 | 65 |
| 2021 October | 47 | 36 | 83 |
| 2021 September | 32 | 43 | 75 |
| 2021 August | 32 | 36 | 68 |
| 2021 July | 43 | 28 | 71 |
| 2021 June | 30 | 29 | 59 |
| 2021 May | 30 | 30 | 60 |
| 2021 April | 85 | 56 | 141 |
| 2021 March | 43 | 31 | 74 |
| 2021 February | 21 | 30 | 51 |
| 2021 January | 41 | 39 | 80 |
| 2020 December | 28 | 16 | 44 |
| 2020 November | 31 | 25 | 56 |
| 2020 October | 23 | 23 | 46 |
| 2020 September | 21 | 11 | 32 |
| 2020 August | 35 | 16 | 51 |
| 2020 July | 20 | 12 | 32 |
| 2020 June | 22 | 14 | 36 |
| 2020 May | 44 | 11 | 55 |
| 2020 April | 19 | 16 | 35 |
| 2020 March | 34 | 12 | 46 |
| 2020 February | 29 | 15 | 44 |
| 2020 January | 33 | 19 | 52 |
| 2019 December | 33 | 27 | 60 |
| 2019 November | 28 | 15 | 43 |
| 2019 October | 18 | 7 | 25 |
| 2019 September | 29 | 25 | 54 |
| 2019 August | 19 | 15 | 34 |
| 2019 July | 16 | 23 | 39 |
| 2019 June | 18 | 11 | 29 |
| 2019 May | 20 | 18 | 38 |
| 2019 April | 49 | 37 | 86 |
| 2019 March | 24 | 20 | 44 |
| 2019 February | 22 | 24 | 46 |
| 2019 January | 17 | 23 | 40 |
| 2018 December | 83 | 41 | 124 |
| 2018 November | 79 | 14 | 93 |
| 2018 October | 60 | 29 | 89 |
| 2018 September | 51 | 12 | 63 |
| 2018 August | 57 | 16 | 73 |
| 2018 July | 39 | 18 | 57 |
| 2018 June | 46 | 8 | 54 |
| 2018 May | 45 | 10 | 55 |
| 2018 April | 63 | 16 | 79 |
| 2018 March | 43 | 13 | 56 |
| 2018 February | 52 | 12 | 64 |
| 2018 January | 36 | 14 | 50 |
| 2017 December | 48 | 22 | 70 |
| 2017 November | 45 | 27 | 72 |
| 2017 October | 28 | 17 | 45 |
| 2017 September | 39 | 17 | 56 |
| 2017 August | 32 | 18 | 50 |
| 2017 July | 35 | 13 | 48 |
| 2017 June | 42 | 13 | 55 |
| 2017 May | 36 | 24 | 60 |
| 2017 April | 38 | 10 | 48 |
| 2017 March | 18 | 24 | 42 |
| 2017 February | 30 | 21 | 51 |
| 2017 January | 28 | 18 | 46 |
| 2016 December | 47 | 7 | 54 |
| 2016 November | 50 | 9 | 59 |
| 2016 October | 92 | 15 | 107 |
| 2016 September | 117 | 12 | 129 |
| 2016 August | 177 | 8 | 185 |
| 2016 July | 150 | 4 | 154 |
| 2016 June | 119 | 0 | 119 |
| 2016 May | 138 | 0 | 138 |
| 2016 April | 103 | 0 | 103 |
| 2016 March | 92 | 0 | 92 |
| 2016 February | 117 | 0 | 117 |
| 2016 January | 104 | 0 | 104 |
| 2015 December | 111 | 0 | 111 |
| 2015 November | 119 | 0 | 119 |
| 2015 October | 108 | 0 | 108 |
| 2015 September | 71 | 0 | 71 |
| 2015 August | 79 | 0 | 79 |
| 2015 July | 78 | 0 | 78 |
| 2015 June | 45 | 0 | 45 |
| 2015 May | 54 | 0 | 54 |
| 2015 April | 11 | 0 | 11 |
Show all
